London, UK, 1 December 2016 – ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today confirmed that GSK, its distributor in Brazil, has finalised an agreement with the Brazilian Ministry of Health (MoH) for the supply of Tivicay® (dolutegravir). This is the largest tender agreement to date for Tivicay and follows the MoH’s announcement on September 28th that the medicine would be made available to people living with HIV (PLHIV) who have never been on treatment as well as in third-line therapy for patients who have been on treatment previously under the national health programme from January 2017 onwards.

Under the agreement, ViiV Healthcare will provide the Brazilian MoH with approximately 1.3 million packs of dolutegravir 50mg tablets in 2017, to be prescribed to approximately 100,000 PLHIV in Brazil.[1] The MoH has now updated national treatment guidelines in Brazil to recommend dolutegravir as preferred first line therapy for treatment-naive patients, as well as third line therapy for treatment-experienced patients, and in post-exposure prophylaxis (PEP).

Jacopo Andreose, VP Head of International, ViiV Healthcare said: “This agreement with the Brazilian Ministry of Health represents another important milestone in our commitment to ensure more options for HIV treatments are available for patients in countries where there is significant need. An agreement on this scale truly showcases our ability as a company to deliver on our promise to accelerate access to innovative HIV treatments all over the world.”

For dolutegravir to be made available on the national health programme in Brazil demonstrates ViiV Healthcare’s strategy to partner with governments to promote broad access to the medicine to those greatest in need, taking into consideration the country gross-national income (GNI), burden of the HIV epidemic and specific associated needs at a national level.

According to UNAIDS, Brazil has the highest prevalence of HIV in Latin America, with 47% of the estimated 1.6 million PLHIV in the region (approximately 730,000 people) living in Brazil.[2] The MoH has reported that 48,000 new patients initiated HIV treatment in 2016.[3]

About dolutegravir

Dolutegravir (Tivicay®) is an integrase strand transfer inhibitor (INSTI) for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. Tivicay is approved in over 90 countries across North America, Europe, Asia, Australia, Africa and Latin America.

Tivicay is a registered trademark of the ViiV Healthcare group of companies.

Important Information about Tivicay® (dolutegravir)

FDA Indication and Usage: Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Use of Tivicay in INSTI-experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of Tivicay 50 mg twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R.

Important Safety Information for Tivicay® (dolutegravir)

Contraindication: Tivicay is contraindicated (1) in patients with previous hypersensitivity reaction to dolutegravir, and (2) in patients receiving dofetilide (antiarrhythmic) due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events.

Hypersensitivity Reactions: Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury. The events were reported in 1% or fewer subjects receiving Tivicay in Phase 3 clinical trials. Discontinue Tivicay and other suspect agents immediately if signs or symptoms of hypersensitivity reaction develop, (including but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters or peeling of the skin, oral blisters or lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema, difficulty breathing.) Monitor clinical status, including liver aminotransferases, and initiate appropriate therapy. Delay in stopping treatment with Tivicay or other suspect agents after the onset of hypersensitivity may result in a life-threatening reaction. Tivicay is contraindicated in patients who have experienced a hypersensitivity reaction to dolutegravir.

Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Coinfection: Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of Tivicay. In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with Tivicay are recommended in patients with underlying hepatic disease such as hepatitis B or C.

Fat Redistribution: Redistribution/accumulation of body fat has been observed in patients receiving antiretroviral therapy.

Immune Reconstitution Syndrome: During the initial phase of treatment, immune reconstitution syndrome can occur, which may necessitate further evaluation and treatment. Autoimmune disorders have been reported to occur in the setting of immune reconstitution; the time to onset is more variable and can occur many months after initiation of treatment.

Adverse Reactions: The most commonly reported (≥2%) adverse reactions of moderate to severe intensity in treatment naïve adult subjects in any one trial receiving Tivicay in a combination regimen were insomnia (3%), fatigue (2%), and headache (2%).

Drug Interactions: Co-administration of Tivicay with drugs that are strong inducers of UGT1A1 and/or CYP3A4 may result in reduced plasma concentrations of dolutegravir and require dose adjustments of Tivicay.

- Tivicay should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral iron supplements, oral calcium supplements, or buffered medications.

- Consult the full Prescribing Information for Tivicay for more information on potentially significant drug interactions, including clinical comments.

Pregnancy: Pregnancy category B. Tivicay should be used during pregnancy only if the potential benefit justifies the potential risk. An Antiretroviral Pregnancy Registry has been established.

Breastfeeding: Breastfeeding is NOT recommended due to the potential for HIV transmission and the potential for adverse reactions in nursing infants.

Paediatric Patients: Safety and efficacy of Tivicay has not been established in children younger than 12 years old, or weighing <40 kg, or in INSTI-experienced paediatric patients with documented or clinically suspected INSTI resistance.

Please visit the following link for the full US prescribing and patient information:


– Ends –

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit

About GSK

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

ViiV Healthcare Media enquiries: Sébastien Desprez
Isabelle Scali
+44 (0) 20 8380 6275
+44 (0) 20 047 4733
  Marc Meachem +1 919 483 8756
GSK Global Media enquiries: Simon Steele +44 (0) 20 8047 3763
  Rachel Jaikaran +44 7909 00240
  David Daley +44 (0) 20 8047 2615
Analyst/Investor enquiries: Ziba Shamsi +44 (0) 20 8047 5543
  Tom Curry
+ 1 215 751 5419
  Gary Davies +44 (0) 20 8047 5503
  James Dodwell +44 (0) 20 8047 2406
  Jeff McLaughlin +1 215 751 7002


[1] Ministry of Health, Brazil. Health offer best treatment in the world for HIV / AIDS. 26 September 2016. Last accessed September 2016.

[2] Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report, p.84 & A13. September 2014. Last accessed November 2016.

[3] Ministry of Health, Brazil. Health offer best treatment in the world for HIV / AIDS. 26 September 2016. Last accessed November 2016.

Media contacts

For our corporate press office, email: Rachel Jaikaran

OR call +44 7823 523 755

For US-specific media enquiries,

OR call +1 919 605 4521

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.